Barclays
SRTA

Barclays’s Strata Critical Medical Inc SRTA Stock Holding History

Barclays’s Portfolio SRTA Stock Details SRTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Sell
60,869
-44,603
-42% -$235K ﹤0.01% 3460
2026
Q1 		$441K Sell
105,472
-93,300
-47% -$449K ﹤0.01% 3264
2025
Q4 		$956K Buy
198,772
+15,018
+8% +$72.6K ﹤0.01% 3459
2025
Q3 		$930K Sell
183,754
-15,704
-8% -$69.4K ﹤0.01% 3412
2025
Q2 		$804K Buy
199,458
+47,981
+32% +$156K ﹤0.01% 3482
2025
Q1 		$414K Sell
151,477
-28,114
-16% -$101K ﹤0.01% 3637
2024
Q4 		$763K Buy
179,591
+13,437
+8% +$51.2K ﹤0.01% 3559
2024
Q3 		$488K Buy
166,154
+56,079
+51% +$178K ﹤0.01% 3789
2024
Q2 		$383K Sell
110,075
-40,651
-27% -$136K ﹤0.01% 3208
2024
Q1 		$430K Sell
150,726
-40,449
-21% -$125K ﹤0.01% 3684
2023
Q4 		$675K Buy
191,175
+54,864
+40% +$157K ﹤0.01% 3698
2023
Q3 		$353K Buy
136,311
+94,149
+223% +$331K ﹤0.01% 2996
2023
Q2 		$166K Buy
42,162
+1,341
+3% +$4.25K ﹤0.01% 3338
2023
Q1 		$138K Buy
40,821
+13,583
+50% +$55.4K ﹤0.01% 4000
2022
Q4 		$97.5K Buy
27,238
+12,863
+89% +$55K ﹤0.01% 4238
2022
Q3 		$58K Sell
14,375
-932
-6% -$4.79K ﹤0.01% 3735
2022
Q2 		$68K Buy
15,307
+3,312
+28% +$23.9K ﹤0.01% 3923
2022
Q1 		$102K Buy
+11,995
New +$84.3K ﹤0.01% 3769

Other funds holding SRTA

TP
Third Point New York $4.68B AUM 37.3% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $337M AUM 63.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
PLC
Pillsbury Lake Capital San Francisco, California $366M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Barclays's SRTA Position: Q2 2026 in Review

Barclays reduced its Strata Critical Medical Inc (SRTA) stake by 42% in Q2 2026, selling an estimated $235K and leaving 60,869 shares worth $321K. The position accounts for ﹤0.01% of the portfolio, ranked #3460.

Barclays first reported a position in SRTA in Q1 2022 and has held it in 18 quarters since. The position peaked at $956K in Q4 2025. 139 funds tracked by Wall St. Rank hold SRTA as of Q2 2026.

  • Barclays held 60,869 shares of Strata Critical Medical Inc worth $321K as of Q2 2026.
  • Barclays sold 44,603 Strata Critical Medical Inc shares in Q2 2026, an estimated $235K.
  • Strata Critical Medical Inc made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #3460 holding.
  • Barclays first reported a position in Strata Critical Medical Inc in Q1 2022 and has held it in 18 quarters since.
  • Barclays's Strata Critical Medical Inc position peaked at $956K in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Strata Critical Medical Inc as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.